2,650 results on '"Willemze, R."'
Search Results
2. Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group.
3. Case 49. Adult T-cell leukemia/lymphoma
4. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
5. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium
6. Neuronal control of experimental colitis occurs via sympathetic intestinal innervation
7. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
8. Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma
9. Itch as a quality of life indicator in patients with cutaneous T cell lymphoma
10. DOP063 Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitis
11. Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes
12. Deregulation of JAK2 signaling underlies primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma
13. P716 Beta-blocker use is associated with a higher relapse risk of inflammatory bowel disease – a Dutch retrospective cohort study
14. P069 Sympathetic but not vagal intestinal innervation regulates murine dextran sodium sulphate-induced colitis
15. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT
16. Bloedziekten
17. Should we be imaging lymph nodes at initial diagnosis of early‐stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*
18. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop*
19. YNK01, an Oral Cytosine Arabinoside Derivative in Acute Myeloid Leukemia and Chronic Myeloid Leukemia
20. Postremission Therapy: The Role of Allogeneic Bone Marrow Transplantation in Acute Myelogenous Leukemia: An Analysis of the AML8A EORTC-GIMEMA Protocol
21. Mechanisms of Acquired ARA-C and DAC Resistance in Acute Myeloid Leukemia (AML): Development of a Model for the Study of Mutational Loss of Deoxycytidine Kinase (DCK) Activity
22. XV. Primary cutaneous lymphomas
23. Biology of Stem Cell Mobilization Induced by Cytokines
24. Presence of Epstein-Barr Viral DNA and EBV Latent Gene Products in Hodgkin and Non-Hodgkin Lymphoma: High Expression of EBV-DNA Sequences in Non-Hodgkin Lymphoma with Variable Numbers Of CD30-Positive Cells
25. Adhesion Molecules Involved in the Extravasation of Lymphocytes in Lymphoid Organs and Chronically Inflamed Tissues
26. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
27. Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL
28. Clear cell acanthoma on the dorsum of the hand
29. Therapie maligner kutaner Lymphome
30. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group
31. A-207 Towards guidelines for clinical management of cutaneous lymphoproliferative disorders: an 2024 update.
32. A-144 Exploring the association of CD30+ Lymphoproliferative Disorders and Inflammatory Conditions in a Dutch Cohort.
33. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
34. High Levels of Circulating Hematopoietic Progenitor Cells after Continuous Infusion of High Dose Interleukin-2 in Cancer Patients
35. Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia in First Remission: First Dutch Prospective Study
36. A Randomized Comparison of Intensive Maintenance Treatment for Adult Acute Myelogenous Leukemia Using Either Cyclic Alternating Drugs or Repeated Courses of the Induction-Type Chemotherapy: AML-6 Trial of the EORTC Leukemia Cooperative Group
37. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature
38. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases
39. Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease
40. Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
41. Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants
42. Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020
43. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study
44. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study
45. Incidence of mycosis fungoides and Sezary syndrome in the Netherlands between 2000 and 2020
46. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study
47. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON
48. Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia
49. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
50. Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.